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Abstract
In recent years, the use of the consensus definitions of acute
kidney injury (RIFLE and AKIN) in the literature has increased
substantially. This indicates a highly encouraging acceptance by
the medical community of a unifying definition for acute kidney
injury. This is a very important and positive step in the right
direction. There remains some variation in how the criteria are
interpreted and used in the literature, including use/nonuse of urine
output criteria, use of change in estimated glomerular filtration rate
rather than change in creatinine, and choice of baseline creatinine.
The present review is intended to aid the reader in critically
appraising studies using these consensus definitions. Since no
single definition will be perfect, a logical next step would be to
reconcile existing definitions, moving the medical community
towards using a single consensus definition as has been done with
sepsis and acute lung injury/acute respiratory distress syndrome.
As new data emerge, integration of novel biomarkers into the
consensus definition will be a welcome refinement.
Introduction
Acute kidney injury (AKI) is an important clinical issue,
especially in the critical care setting. AKI has been shown in
multiple studies to be a key independent risk factor for
mortality, even after adjustment for demographics, severity of
illness and other relevant factors [1]. Despite recent evidence
suggesting some improvement in outcomes over time [2,3],
AKI remains a formidable problem. It is a complex clinical
syndrome for which there was no accepted definition for
quite some time. Reported incidence and mortality rates vary
widely in the literature, with incidence ranging from 1 to 31%
and mortality from 28 to 82% [1,4]. This wide variation stems
not only from the diverse patient populations in the different
studies, but also from the disparate criteria used to define AKI
in these studies. Over 30 definitions of acute renal failure/AKI
have been used in the literature. These range from looser
criteria such as a 25% increase in serum creatinine from
baseline to more stringent definitions such as the need for
renal replacement therapy (RRT). The more permissive the
definition used in a particular study, the higher the incidence
of AKI and the lower the associated mortality. The reverse is
true with more restrictive AKI criteria [4]. As a result,
comparison between different studies has been difficult.
A unifying definition was needed to bring order to the AKI
literature, in much the same way that consensus definitions
for sepsis, acute respiratory distress syndrome and acute
lung injury have done. After an initial attempt to stratify AKI for
severity [5], a consensus definition was published by the
Acute Dialysis Quality Initiative (ADQI) [6]. A modified version
was proposed recently by the Acute Kidney Injury Network
(AKIN) [7]. Both definitions are briefly described here, and
issues relevant to their use and validation in the literature will
be reviewed. This is not intended to be a systematic review
as one has been recently published [8]. Instead, the present
review is intended to aid the reader in critically appraising
studies using these consensus definitions.
RIFLE classification
Background
In 2004 the ADQI group published their consensus definition
for AKI, the Risk–Injury–Failure–Loss–Endstage renal disease
(RIFLE) classification [6]. Being a definition, RIFLE is
intended to establish the presence or absence of the clinical
syndrome of AKI in a given patient or situation, and to
describe the severity of this syndrome. The classification was
not designed to predict mortality or adverse outcomes,
although it is logical to assume that more severe disease
should result in worse outcome.
RIFLE uses two criteria: change in blood creatinine or
glomerular filtration rate (GFR) from a baseline value, and
urine flow rates per body weight over a specified time period
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(Figure 1). Patients are classified on the basis of the criterion
that places them in the worse category. Risk is the least
severe category of AKI, followed by Injury, and Failure is the
most severe category. RIFLE is therefore also able to
describe the change or trend in AKI severity over time.
RIFLE studies
Since the classification’s publication, several original investi-
gations using RIFLE have been published [8-32]. These
studies have varying objectives, including description of the
epidemiology of AKI, association between the presence and
severity of AKI with clinical outcome, evaluation of biomarkers
or devices for the diagnosis of AKI, and describing renal
outcome. Ricci and colleagues recently published a syste-
matic review of 24 of these studies [8]. The majority of the
studies looked at patients in general or specialized intensive
care unit (ICU) settings [8], one study analyzed all hospital
admissions over a 3-year period [9], while another study
made a population-based estimate of AKI incidence in
Scotland [10]. Most studies were retrospective in design,
and used only the creatinine/GFR criterion. In only 12% of
the analyzed population were the creatinine and urine output
criteria used together; furthermore, only two of the included
studies were prospective in design [11,12].
The analysis of pooled data showed a stepwise increase in
relative risk for death with increasing AKI severity (Figure 2)
(Risk, 2.40; Injury, 4.15; Failure, 6.37, with respect to non-AKI
patients) [8]. This biological gradient generally held true
regardless of the type of patient population studied
(Figure 3), with the possible exception of patients dialyzed for
AKI. Two of the studies included in the systematic review
looked exclusively at this population; the authors staged AKI
severity at initiation of RRT. In their cohort, Bell and
colleagues reported a 30-day mortality of 23.5%, 22.0% and
57.9% in patients with Risk, Injury and Failure, respectively
[13]. Maccariello and colleagues reported similar mortality in
the three groups (Risk, 72%; Injury, 79%; Failure, 76%) [14].
Since the e-publication of the systematic review [8], at least
16 new original investigations using RIFLE were published
[16-31]. Among them, the largest is a retrospective analysis
of over 120,000 patients evaluated on the first ICU day
[15,24]. This study again confirmed a stepwise increase in
risk of death going from Risk to Injury to Failure [24]. Overall,
these studies demonstrate that the worse the RIFLE class,
the higher the mortality [8-12,15-17,19-25,31], the longer the
ICU stay and hospital stay [15,24,31], and the lower renal
recovery (for example, higher serum creatinine at hospital
Figure 1
RIFLE and AKIN classifications for acute kidney injury. Risk–Injury–Failure–Loss–Endstage renal disease (RIFLE) and Acute Kidney Injury Network
(AKIN) classifications for acute kidney injury (adapted from [6,7]). ARF, acute renal failure; Cr, creatinine; GFR, glomerular filtration rate.discharge) [17]. It is important to note, however, that among a
total of over 200,000 patients included in all these studies, less
than 2% of patients were part of prospective studies [11,12].
Limitations of RIFLE
The RIFLE classification is not without its limitations. First, any
clinical definition of AKI signals its presence when there has
already been a decline in the GFR, whereas biomarkers are
able to make the diagnosis at an earlier stage; for example,
when there has been tubular damage even before there is a
change in the GFR. On the other hand, biomarkers may
signal damage at the molecular and cellular level that may not
necessarily translate into a clinically relevant reduction in the
GFR later on.
Second, the use of 6-hour and 12-hour urine criteria make
RIFLE unwieldy for retrospective studies, since such data are
not collected as part of routine clinical practice. Not only is
urine output affected by diuretic use, but such details can
only be accurately assessed in patients with a urinary
catheter. In addition, the urine output criterion may not match
well with the patient’s respective creatinine criterion.
In the aforementioned systematic review, the relative risk for
death among studies that used both creatinine and urine
output criteria was lower than in those using the creatinine
criterion only [8]. This finding is congruent with prior obser-
vations. In a review of 10 studies, Hoste and Kellum noted
that patients in the Risk class defined by the creatinine
criterion were more severely ill than those in the same class
defined by the urine output criterion alone [33]. Hoste and
colleagues also observed that patients in Failure based on
the GFR criterion had a slightly higher mortality than those in
Failure based on the urine output criterion [15]. In a study by
Cruz and colleagues, RIFLE classes (using creatinine and
urine output criteria together) were the strongest predictor of
ICU mortality in multivariable analysis [11]. When the analysis
was repeated based only on change in the creatinine
criterion, however, RIFLE class was an independent predictor
but the statistical model was inferior. When analysis was
performed based only on the urine output criterion, RIFLE
class did not emerge as an independent predictor.
Altogether these findings highlight a potential effect of the
use or nonuse of the urine output criterion on the overall
predictive capacity of RIFLE in a particular study. Further-
more, they suggest an imbalance between the creatinine and
urine output criteria.
A third limitation of RIFLE is that the creatinine/GFR criterion
is based on change from a baseline value, which is often not
available. In this scenario, the ADQI recommends a creatinine
estimation based on the Modification of Diet in Renal Disease
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Figure 2
Mortality by RIFLE class. Mortality (relative risk (RR) and 95%
confidence interval) by Risk–Injury–Failure–Loss–Endstage renal
disease class (data from [8]). AKI, acute kidney injury.
Figure 3
RIFLE class and mortality in different patient populations. Risk–Injury–Failure–Loss–Endstage renal disease class and mortality in different patient
populations (data from [8]). NonAKI, no acute kidney injury; Cr, creatinine; ICU, intensive care unit; RR, relative risk.(MDRD) formula, assuming a normal GFR of approximately
75 to 100 ml/min/1.73 m2 [6,24,32]. Although a very con-
venient and useful rule, it is not known how valid this
assumption is. This is discussed further below.
Fourth, investigators may be tempted to use the change in
estimated GFR in place of the (true) GFR criterion, as some
studies have already done [9,10,32]. This can be considered
inherently incorrect since the MDRD equation, as with all
GFR or creatinine clearance equations, is valid only in steady-
state conditions [34,35], and is certainly invalid in a situation
where renal function is rapidly changing (that is, AKI) [36]. In
situations where the estimated GFR is used inappropriately,
the derived conclusions could be misleading.
Fifth, recent studies have shown that smaller changes in
creatinine than those specified under class Risk, such as an
absolute increase as small as 0.3 mg/dl, are associated with
poor outcomes [37].
Lastly, RIFLE does not take into consideration the nature or
site of the kidney injury. The same could be said, however, for
the consensus definitions for sepsis, acute lung injury, and
acute respiratory distress syndrome [38,39].
The baseline creatinine
When no information on prior renal function is available,
various studies use different ways to define the baseline
creatinine – such as the creatinine at hospital admission, the
creatinine at ICU admission, or the creatinine estimated from
the MDRD formula as was suggested by the ADQI [6,34]. In
a retrospective study, E Hoste (personal communication, with
permission) looked at the crude mortality in various RIFLE
classes, using seven different options for baseline creatinine
(Table 1). The mortality within each RIFLE category varied by
as much as 7 to 13.9%, depending on which baseline
creatinine was used; nonetheless, a stepwise progression
was still seen going from Risk to Injury to Failure.
Zappitelli and colleagues also addressed the same issue in a
pediatric population, using the modified pediatric RIFLE
classification [18]. As criteria, the pediatric RIFLE classifi-
cation uses changes in the estimated creatinine clearance by
the Schwartz formula [40]. In their study, some patients had a
known baseline creatinine while 41 patients did not [18]. In
this latter group, the authors looked at five different
possibilities for baseline creatinine (Table 1). The choice of
baseline creatinine had a marked effect on the prevalence of
AKI. Depending on which baseline creatinine was used, AKI
prevalence could be as low as 12.2% or as high as 82.9%
among pediatric ICU patients. In a noncritically ill group of
patients, the estimated prevalence ranged from 4.6 to 43.1%.
Furthermore, in the subgroup in which information on prior
renal function was available, these five options for estimated
baseline creatinine varied by 0 to 67% from the true baseline
value [18].
This variation should be taken into consideration when
reading and interpreting the literature, as this may have an
effect on the accuracy of estimates of prevalence, incidence,
risk ratios, and so forth. More importantly, it is crucial for
investigators to make every effort to find and use a true
baseline creatinine before resorting to the use of estimates
based on various equations, particularly since chronic kidney
disease is a key risk factor for AKI. Studies evaluating the
validity of use of estimated baseline creatinine, whether from
the MDRD formula or other equations, are needed.
AKIN classification
Background
To extend consensus to scientific societies and healthcare
organizations, the AKIN was created. A number of national
and international societies of nephrology and critical care
endorsed this initiative. One of the tasks of AKIN was further
refinement of the AKI definition. In 2007 a modified version of
the RIFLE classification was published, also known as the
AKIN classification (Figure 1 and Table 2) [7]. Four modifica-
tions are readily recognized: Risk, Injury, and Failure have
been replaced with Stages 1, 2 and 3, respectively; an
absolute increase in creatinine of at least 0.3 mg/dl has been
added to Stage 1; patients starting RRT are automatically
classified as Stage 3, regardless of their creatinine and urine
output; and the outcome categories Loss and Endstage renal
disease have been eliminated.
Some finer points, however, may be overlooked. First, AKIN
recommends ‘exclusion of urinary tract obstructions or …
easily reversible causes of decreased urine output’ and
application of the diagnostic criteria ‘… following adequate
resuscitation when applicable’ [7]. This modification is
intended to exclude transient changes in creatinine or urine
output due to volume depletion or other easily reversible
causes, and addresses to some extent RIFLE’s inability to
exclude pre-renal azotemia. On the other hand, these factors
are virtually impossible to verify in retrospective studies, and
the concept of adequacy of resuscitation is highly variable
among practitioners. Although one might argue that the AKIN
criteria are intended to be used prospectively, one must also
recognize that the vast majority who sought to or will seek to
validate AKIN – or any AKI definition, for that matter – were
and will be retrospective studies, as has occurred with RIFLE.
Interestingly, a small retrospective study attempted to
evaluate this component of AKIN [41]. The authors
concluded that the association of AKI with inhospital mortality
was still significant even when the appropriate fluid challenge
requirement is discarded.
A second crucial, and perhaps under-recognized, difference
between RIFLE and AKIN is the 48-hour timeframe within
which the diagnosis of AKI is made (Table 2) [7]. How this
timeframe would be applied in patients in whom at least
every-other-day creatinine values are not available, such as
patients in the hospital wards, is not clear. This uncertainty is
Critical Care    Vol 13 No 3 Cruz et al.
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AKIN [18]. The authors state ‘AKIN criteria … change in
creatinine should occur within 48h. Because creatinine was
not drawn daily in our non-critically ill group, we did not
include this requirement’.
Third, although diagnosis of AKI is based on changes over
the course of 48 hours, staging occurs over a slightly longer
timeframe (Table 2).
Finally, the GFR criteria have been eliminated, which helps to
discourage the incorrect use of changes in the estimated
GFR for AKI diagnosis [36], as has been mentioned above.
The reference creatinine
Yet another important concept in AKIN is the use of a
reference creatinine for the diagnosis of AKI. A diagnosis of
AKI is made on the basis of two serum creatinine values
within a 48-hour period. This would circumvent the problem
of not knowing the patient’s true baseline creatinine. The
reference creatinine is the lowest creatinine within a 48-hour
timeframe used to diagnose AKI [7,42].
The differences between RIFLE and AKIN in classifying a
patient are illustrated in the hypothetical example of a
Caucasian male, whose baseline creatinine is not known but
is estimated at 1.0 mg/dl, with a slow increase in creatinine in
the ICU of 0.1 mg/dl/day (Table 3). RIFLE and AKIN cate-
gories based on serum creatinine are shown for each ICU
day. Between days 1 and 16, at no point was there an
increase in creatinine of at least 0.3 mg/dl within a 48-hour
timeframe. Based on AKIN criteria, the patient would not be
diagnosed as AKI until day 17. At this point, the reference
creatinine would be the lower of the creatinine values in the
two previous days (that is, 2.4 mg/dl), and this is the
creatinine value used to stage the patient’s AKI. As demon-
strated, the difference may be quite striking.
AKIN studies
At least eight studies have used the AKIN classification
[16,18,30,41,43-46], including that by Ostermann and
Chang recently published in Critical Care [46].
The largest of these studies is a retrospective reanalysis of
the Australia and New Zealand Intensive Care Society
database [16], which compared RIFLE and AKIN on the first
ICU day only. Estimates of prevalence and crude mortality
were very similar between the two classification schemes.
The authors concluded that, ‘Compared to the RIFLE criteria,
the AKIN criteria do not materially improve the sensitivity,
robustness and predictive ability of the definition and
classification of AKI in the first 24 h after admission to ICU’
[16]. This study, however, has some limitations. As with all
retrospective studies, urine output criteria were not used as
they were intended to be used. Only 24-hour urine output
was available, and patient weights were not known. Although
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Table 1
Acute kidney injury mortality (adults) and prevalence (pediatric) by different baseline creatinine values
No acute  Risk  Injury  Failure 
Method for estimating baseline creatinine kidney injury (%) (%) (%)
Crude mortality by RIFLE class (adults)
Hospital admission 12.4 21.7 34.5 40.6
ICU admission 12.7 21.7 31.2 38.4
Lower of hospital or ICU admission 10.4 16.0 36.0 41.5
Estimate from MDRD formula 5.7 12.7 25.2 34.9
Lower of hospital or ICU admission or MDRD estimate 7.2 12.9 24.3 35.7
Nadir creatinine (first week) 9.7 13.1 25.9 30.1
Nadir creatinine (whole admission) 8.9 11.0 22.1 28.7
Acute kidney injury prevalence by pediatric RIFLE class (pediatric ICU)
Estimated creatinine clearance of 120 ml/min/1.73 m2 36.5 17.1 24.4 22.0
Estimated creatinine clearance of 100 ml/min/1.73 m2 17.1 14.6 36.6 31.7
ICU admission 87.9 7.3 2.4 2.4
Normal value for age and gender (minimum) 12.2 12.2 39.0 36.6
Normal value for age and gender (maximum) 46.3 14.6 17.1 22.0
Adapted from E Hoste (personal communication, with permission) and [18]. ICU, intensive care unit; MDRD, Modification of Diet in Renal Disease.Critical Care    Vol 13 No 3 Cruz et al.
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Table 2
Comparison between Risk–Injury–Failure–Loss–Endstage renal disease and Acute Kidney Injury Network classifications
RIFLE classification AKIN classification
Risk, Injury, and Failure Stages 1, 2 and 3 
Loss and Endstage renal disease describe renal outcome after  Not used 
acute kidney injury episode 
Uses change in creatinine or glomerular filtration rate, in addition to  Uses change in creatinine, in addition to urine output criteria 
urine output criteria 
Risk: increased creatinine × 1.5 or glomerular filtration rate  Stage 1: increased creatinine x 1.5 or ≥0.3 mg/dl
decrease >25%
Stage not specified for patients starting renal replacement therapy Patients starting renal replacement therapy are classified as Stage 3, 
regardless of serum creatinine or urine output
Proposed timeframe of 1 week specified for making diagnosis of  Acute kidney injury diagnosis is based on a change between two 
acute kidney injury creatinine values within a 48-hour perioda
Not specified Diagnostic criteria to be used only “after an optimal state of hydration 
has been achieved”
aAlthough the diagnosis of acute kidney injury is based on changes over the course of 48 hours, staging occurs over a slightly longer timeframe.
One week was the timeframe proposed by the Acute Dialysis Quality Initiative group [7].
Table 3
Acute Kidney Injury Network and Risk–Injury–Failure–Loss–Endstage renal disease classifications: an illustrative examplea
RIFLE AKIN 
ICU day Creatinine classification classification Comment
1 1 No AKI No AKI
2 1.1 No AKI No AKI
3 1.2 No AKI No AKI
4 1.3 No AKI No AKI
5 1.4 No AKI No AKI
6 1.5 Risk No AKI 1.5 × estimated baseline creatinine of 1.0
7 1.6 Risk No AKI
8 1.7 Risk No AKI
9 1.8 Risk No AKI
10 1.9 Risk No AKI
11 2 Injury No AKI 2 × estimated baseline creatinine of 1.0
12 2.1 Injury No AKI
13 2.2 Injury No AKI
14 2.3 Injury No AKI
15 2.4 Injury No AKI Reference creatinine for AKIN
16 2.5 Injury No AKI
17 3 Failure Stage 1 Δ >0.3 with respect to ICU days 15 and 16, 3 x estimated baseline 
creatinine of 1.0
18 3.9 Failure Stage 1 Not yet 2 × reference creatinine
aA 65-year-old white male, baseline creatinine not known but estimated at 1.0 mg/dl with the Modification of Diet in Renal Disease formula,
admitted to the intensive care unit (ICU). AKI, acute kidney injury.the authors attempted to modify the criteria (in a 24-hour
period: Risk, <35 ml/hour; Injury, <21 ml/hour; and Failure,
<4 ml/hour) [15], these estimates were ultraconservative. In
fact, a 70 kg man with a 24-hour urine output <21 ml/hour in
this study would have a 24-hour urine output <0.3 ml/kg/hour.
Such a patient would technically qualify for Failure/Stage 3,
rather than Injury/Stage 2. More importantly, this study looks
only at the first ICU day; therefore, the 48-hour timeframe of
AKIN does not come into play at all. Perhaps this is not the
optimal study design for accurately comparing the two classi-
fications. Nevertheless, this study raises some interesting
points: would estimates of AKI prevalence differ between
RIFLE and AKIN when we look at late AKI (that is, after the
first ICU day)? If so, would the relationships between clinical
outcome (for example, mortality) and AKI stages/classes
change?
A retrospective study looking at the first 72 hours of ICU
admission showed a higher prevalence of AKI with RIFLE
compared with AKIN [44]. The authors noted a stepwise
increase in mortality going from Risk to Injury to Failure
(29.6%, 32.4% and 42.2%, respectively). In contrast,
mortality rates were 34.7%, 29.2% and 40.6% for Stage 1,
Stage 2 and Stage 3, respectively. In a small retrospective
single-center study, the authors concluded that AKIN does
not seem to improve on the ability of the RIFLE criteria in
predicting hospital mortality of critically ill patients [45].
The largest study to look at patients during their entire ICU
stay is a retrospective reanalysis of 22,303 patients in the
Riyadh Intensive Care Program database [46]. Like most
retrospective studies, the investigators were unable to use
the urine output criteria of AKIN. Although the published
AKIN criteria specify ‘an absolute increase of  ≥0.3 mg/dl’
within 48 hours, the authors applied the criteria ‘without
specifying the direction of change’; that is, they classified
patients with falling creatinine values as having AKI as well.
This adjustment of the AKIN criteria is certainly compatible
with clinical judgment. In their analysis, only AKI Stage 3 was
an independent risk factor for ICU mortality. Surprisingly, AKI
Stage 1 appeared to have a protective effect (odds ratio =
0.8, 95% confidence interval = 0.73 to 0.91). The authors
concluded that the 48-hour window for AKI diagnosis may
miss patients with a slow but significant decline in renal
function. Furthermore, they hypothesize that using RRT as a
criterion for Stage 3 may have a confounding effect on the
predictive power of the classification. These issues remain to
be resolved by further, ideally prospective, studies using both
creatinine and urine output criteria.
Limitations of AKIN
The AKIN criteria have partially addressed some issues with
RIFLE. First, as mentioned, the elimination of the GFR
criterion reduces variation in use of the criteria. Second, the
negative prognostic value of smaller changes in creatinine
has been recognized [37]. Third, although the classification
still does not define the nature of renal injury, some attempt
has been made to exclude easily reversible causes of
azotemia (for example, from volume depletion or urinary
obstruction) from being classified as AKI.
Other limitations similar to RIFLE remain, however: the fact
that an AKI diagnosis based on clinical parameters can be
considered pathophysiologically late, and issues related to
the urine output criterion, among others. In addition to these,
users of the definition may be confused about the correct use
of the reference creatinine, the 48-hour timeframe (for AKI
diagnosis) and the 1-week timeframe (for AKI staging)
(Table 2) [7]. There may be difficulty applying these criteria to
patients without daily (or at least every-other-day) creatinine
measurements [18], or to those who are admitted with a high
creatinine that then decreases. Although we would clinically
recognize such a patient as being admitted with resolving
AKI, technically in such a patient there would be no ‘abrupt
(within 48 hour) reduction in kidney function’ on which to
base the AKI diagnosis. As suggested by the Riyadh study,
the published AKIN criteria also could potentially miss
patients with slow but significant increases in creatinine [46].
Owing to a lack of universal guidelines for RRT initiation, it is
at present a very subjective decision. Using RRT as a
criterion for AKI staging may therefore have resulted in an
unforeseen confounding effect.
Altogether the cynic may consider these issues as semantics –
these seemingly minor technical points may be significant in
terms of reported epidemiology of AKI, as well as coding
practices for reimbursement.
Time for reappraisal
The essential components of a workable consensus definition
are that the definition should clearly establish the presence or
absence of the disease, must give an idea of the severity of
the disease, should correlate disease severity with outcome,
and, most importantly, should be easy to understand and
apply in a variety of clinical and research settings. In recent
years, the use of the consensus definitions of AKI (RIFLE and
AKIN) in the literature has increased substantially. This
increase indicates a highly encouraging acceptance by the
medical community of a unifying definition for AKI. This is a
very important and positive step in the right direction. There
remains some variation in how the criteria are interpreted and
used in the literature, including use/nonuse of the urine
output criterion, use of the change in the estimated GFR
rather than the change in creatinine, and the choice of base-
line creatinine.
Future studies evaluating AKI criteria should ideally be
prospective in order to improve the quality of data collection
and to assess ease of use. Some of these studies could
address the utility of such classifications for guiding clinicians
regarding different interventions of AKI therapy. One example
would be the timing of RRT initiation. While in the past the
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versus late), AKIN has proposed that the RIFLE/AKIN criteria
may provide the possibility of a more quantitative charac-
terization of timing [47].
It is imperative to recognize that no single definition will be
perfect. A logical next step would be to reconcile existing
definitions, moving the medical community towards using a
single consensus definition as has been done with sepsis
and acute lung injury/acute respiratory distress syndrome.
Proposed enhancements would include retaining the
minimum absolute change of ≥0.3 mg/dl, but would include
both an abrupt increase and a decrease in serum creatinine,
use of a timeframe longer than 48 hours for AKI diagnosis to
avoid missing patients with slow but significant increases in
creatinine, and using the same timeframe for both diagnosis
and staging of AKI to avoid potential confusion, among
others. As new data emerge, integration of novel biomarkers
into the consensus definition will be a welcome refinement. In
summary, all of these considerations remain in favor of a new
and definitive ecumenic definition/classification of AKI. The
time for “i-RIFLE” (improved-RIFLE) has come.
Conclusions
The present review indicates that use of the consensus
definitions of AKI (RIFLE and AKIN) in the literature has
increased substantially, indicating a highly encouraging
acceptance by the medical community of a unifying definition.
AKI diagnosed using either classification, however, is
associated with poor clinical outcome. A worse RIFLE class
is associated with higher mortality, and with a longer ICU stay
or hospital stay. There is some variation in how the
consensus criteria are interpreted and used in the literature,
including use/nonuse of the urine output criterion, use of the
change in the estimated GFR rather than the change in
creatinine, and the choice of baseline creatinine. A logical
next step would be to reconcile existing definitions, moving
the medical community towards using a single consensus
definition that can be easily and uniformly applied.
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